Cryoablation appears to work best in specific subtypes of breast cancer, particularly those that are early-stage, hormone receptor-positive (ER+/PR+), and HER2-negative (HER2-), especially tumors that are small, low-grade, and unifocal. This evidence concerns the gene NR4A1 and breast cancer.